Welcome to our dedicated page for Tiziana Life Sciences Com news (Ticker: TLSA), a resource for investors and traders seeking the latest updates and insights on Tiziana Life Sciences Com stock.
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) is a clinical-stage biopharmaceutical company whose news flow centers on the development of intranasal foralumab, a fully human anti-CD3 monoclonal antibody, and related immunomodulation programs. Company announcements highlight progress in neuroinflammatory and neurodegenerative indications, including non-active secondary progressive multiple sclerosis, early Alzheimer’s disease, and amyotrophic lateral sclerosis (ALS).
News about Tiziana often covers key clinical milestones. Recent releases describe dosing of patients in a Phase 2 randomized, placebo-controlled trial of intranasal foralumab in early Alzheimer’s disease, including evaluation as monotherapy and in combination with FDA-approved anti-amyloid therapies lecanemab and donanemab. Other updates report on the Expanded Access Program in non-active secondary progressive multiple sclerosis and the acceptance of the company’s ALS Phase 2 trial into the ALS MyMatch Program at the Sean M. Healey & AMG Center for ALS.
Investors following TLSA news can also expect regulatory and safety updates, such as the submission of Development Safety Update Reports to the U.S. Food and Drug Administration, which summarize cumulative exposure and safety findings for intranasal foralumab. Corporate and capital markets news includes insider share purchases by senior leadership, decisions regarding proposed public offerings, and participation in industry conferences like BIO-Europe, the Jefferies London Healthcare Conference, and neuroscience-focused forums.
This news page aggregates these company-issued press releases and related coverage, giving readers a centralized view of Tiziana’s clinical progress, regulatory interactions, strategic initiatives such as the planned spinout of IL-6 asset TZLS-501, and visibility events like ringing the Nasdaq Closing Bell. Users interested in TLSA can review this feed to monitor how Tiziana’s immunotherapy and drug delivery programs evolve over time.
Tiziana Life Sciences (TLSA) announced positive clinical outcomes from its ongoing study on Foralumab for patients with Secondary Progressive Multiple Sclerosis (SPMS) during a recent interview. Conducted at Brigham and Women’s Hospital, the trial highlights the potential of Foralumab, the only fully human anti-CD3 mAb, in managing autoimmune diseases. The treatment has shown favorable safety profiles and effective immune response modulation. Tiziana focuses on innovative drug delivery technologies, aiming to improve patient outcomes by offering alternative routes for immunotherapy.
Tiziana Life Sciences PLC (NASDAQ: TLSA) announced positive clinical results for its second patient with secondary progressive multiple sclerosis (SPMS) on June 8, 2022. The patient demonstrated significant clinical improvements, including a 10-30% reduction in microglial activation after three months of treatment with intranasal foralumab. Following the success of the first two patients, the FDA has approved the enrollment of eight more patients under the Expanded Access Program. The company aims to investigate higher dosing levels and expects to enroll a third patient in July 2022.
Tiziana Life Sciences (Nasdaq: TLSA) has announced that Panetta Partners Limited, associated with Executive Chairman Gabriele Cerrone, acquired 18,000 common shares at $0.80 each. This purchase increased Cerrone’s beneficial ownership from 37.58% to 37.60% of the company. Tiziana is focused on developing innovative immunotherapies using alternative drug delivery methods, including intranasal and inhalation approaches, with its lead candidates showing favorable safety profiles and clinical responses.
Tiziana Life Sciences (Nasdaq: TLSA) announced promising clinical results for its intranasal therapy with foralumab in treating Secondary Progressive Multiple Sclerosis (SPMS). Positive outcomes were observed in two patients, demonstrating improvements in PET imaging and neurologic exams after three months of treatment. The FDA has authorized enrollment of an additional eight SPMS patients in the expanded access program. Both patients continue treatment, with the potential for dosage escalation to enhance clinical benefits.
Tiziana Life Sciences (NASDAQ: TLSA) announced that CEO Kunwar Shailubhai will present at the BIO Annual Convention in San Diego from June 13-16, 2022. His focus will be on recent clinical updates for foralumab, an anti-CD3 monoclonal antibody, specifically regarding nasal administration for secondary progressive multiple sclerosis. Additionally, he will discuss the Phase 1b trial for oral capsules of foralumab aimed at treating Crohn’s Disease. Tiziana's management will also conduct one-on-one meetings at the event.
Tiziana Life Sciences (TLSA) announced Dr. Tanuja Chitnis will present clinical data on foralumab, an intranasal anti-CD3 monoclonal antibody, at the CMSC 2022 Annual Meeting from June 1-4. This presentation will focus on a patient with secondary progressive multiple sclerosis treated for six months. The data highlights the potential of foralumab to reduce microglial activation and blood inflammatory markers. The session is scheduled for June 2, 2022, at 5 PM EDT. Foralumab, a unique human anti-CD3 mAb, shows promise in treating autoimmune diseases.
Tiziana Life Sciences (Nasdaq: TLSA) announced the filing of its Annual Report on Form 20-F for the year ended December 31, 2021, on May 23, 2022. Following this filing, the company confirmed it has regained compliance with Nasdaq Listing Rules. Tiziana is focused on developing innovative immunotherapy delivery methods, including intranasal foralumab, which is the only fully human anti-CD3 monoclonal antibody, and milciclib, a pan-CDK inhibitor. The company’s alternative drug delivery technologies aim to enhance efficacy, safety, and tolerability.
Tiziana Life Sciences Ltd (NASDAQ: TLSA) announced that its CEO and CSO, Kunwar Shailubhai, Ph.D., will participate in a fireside chat at the B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference on April 27, 2022, at 2:30 p.m. ET. The discussion will focus on updates regarding the company's innovative biopharmaceutical developments, particularly its intranasal foralumab treatment for Secondary Progressive Multiple Sclerosis. Tiziana aims to revolutionize immunotherapy delivery with its novel approaches.
Tiziana Life Sciences (TLSA) has received FDA approval to expand its Intermediate-Size Patient Population Access program for its intranasal foralumab treatment in secondary progressive multiple sclerosis (SPMS). Following promising clinical responses from two patients, Tiziana aims to initiate treatment for eight additional patients. The dosing regimen will remain at 50 mcg three times a week, with the potential for dose escalation. The study is expected to begin in July 2022, focusing on safety, tolerability, and clinical benefits.
Tiziana Life Sciences (NASDAQ: TLSA) has initiated a Phase 1b clinical trial for foralumab, an oral immunotherapy for mild-to-moderate Crohn's Disease (CD). This trial, expected to conclude by Q4 2022, aims to evaluate the safety and tolerability of a new enteric-coated capsule formulation. The study will also assess clinical responses and pharmacokinetics. Foralumab represents a significant departure from traditional intravenous or subcutaneous therapies, potentially offering improved patient compliance and fewer side effects.